Back to search
FDAFDA · Food and drugs·Recall number D-1170-2023

Digoxin Tablets, USP 0.25mg, 100-count bottles, Rx Only, Manufactured for/Distributed by: Marlex Pharmaceuticals, Inc. New Castle, DE NDC 10135-0748-01

Published September 13, 2023 · Recall initiated: August 25, 2023

Summary

FDA records drug Class II recall D-1170-2023, published September 13, 2023 and initiated August 25, 2023. Recalling firm: Marlex Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 94/100 count bottles; Lot: E3811, expiration date 02/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets, USP 0.25mg contain Digoxin Tablets, USP 0.125mg.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Marlex Pharmaceuticals, Inc.
Distributor
Nationwide in the US.
Lot
E3811, expiration date 02/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Digoxin Tablets, USP 0.25mg, 100-count bottles, Rx Only, Manufactured for/Distributed by: Marlex Pharmaceuticals, Inc. New Castle, DE NDC 10135-0748-01 recalled?

Yes. FDA published recall D-1170-2023 on September 13, 2023. Reported hazard: Labeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets, USP 0.25mg contain Digoxin Tablets, USP 0.125mg.

What should I do if I have this product?

Voluntary: Firm initiated · Letter